Search Results - "VAN CUTSEM, Eric"

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial by Shitara, Kohei, Doi, Toshihiko, Dvorkin, Mikhail, Mansoor, Wasat, Arkenau, Hendrik-Tobias, Prokharau, Aliaksandr, Alsina, Maria, Ghidini, Michele, Faustino, Catia, Gorbunova, Vera, Zhavrid, Edvard, Nishikawa, Kazuhiro, Hosokawa, Ayumu, Yalçın, Şuayib, Fujitani, Kazumasa, Beretta, Giordano D, Cutsem, Eric Van, Winkler, Robert E, Makris, Lukas, Ilson, David H, Tabernero, Josep

“…Trifluridine/tipiracil showed activity and was well tolerated in a phase 2 study of pretreated patients with advanced gastric cancer done in Japan. We…”
Get full text

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer by Golan, Talia, Hammel, Pascal, Reni, Michele, Van Cutsem, Eric, Macarulla, Teresa, Hall, Michael J, Park, Joon-Oh, Hochhauser, Daniel, Arnold, Dirk, Oh, Do-Youn, Reinacher-Schick, Anke, Tortora, Giampaolo, Algül, Hana, O’Reilly, Eileen M, McGuinness, David, Cui, Karen Y, Schlienger, Katia, Locker, Gershon Y, Kindler, Hedy L

“…Approximately 7% of pancreatic cancers occur in patients with a germline mutation in BRCA1 or BRCA2 , an alteration that compromises DNA repair. In a…”
Get full text

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial by Andre, Thierry, Amonkar, Mayur, Norquist, Josephine M, Shiu, Kai-Keen, Kim, Tae Won, Jensen, Benny Vittrup, Jensen, Lars Henrik, Punt, Cornelis J A, Smith, Denis, Garcia-Carbonero, Rocio, Sevilla, Isabel, De La Fouchardiere, Christelle, Rivera, Fernando, Elez, Elena, Diaz, Luis A, Yoshino, Takayuki, Van Cutsem, Eric, Yang, Ping, Farooqui, Mohammed, Le, Dung T

“…In the KEYNOTE-177 study, pembrolizumab monotherapy provided statistically significant and clinically meaningful improvements in progression-free survival…”
Get full text

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer by Mayer, Robert J, Van Cutsem, Eric, Falcone, Alfredo, Yoshino, Takayuki, Garcia-Carbonero, Rocio, Mizunuma, Nobuyuki, Yamazaki, Kentaro, Shimada, Yasuhiro, Tabernero, Josep, Komatsu, Yoshito, Sobrero, Alberto, Boucher, Eveline, Peeters, Marc, Tran, Ben, Lenz, Heinz-Josef, Zaniboni, Alberto, Hochster, Howard, Cleary, James M, Prenen, Hans, Benedetti, Fabio, Mizuguchi, Hirokazu, Makris, Lukas, Ito, Masanobu, Ohtsu, Atsushi

“…TAS-102, a combination of trifluridine and tipiracil in which tipiracil interferes with the deactivation of trifluridine, improved overall and progression-free…”
Get full text

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study by Thuss-Patience, Peter C, MD, Shah, Manish A, MD, Ohtsu, Atsushi, MD, Van Cutsem, Eric, Prof, Ajani, Jaffer A, Prof, Castro, Hugo, MD, Mansoor, Wasat, PhD, Chung, Hyun Cheol, Prof, Bodoky, Gyorgy, Prof, Shitara, Kohei, MD, Phillips, Gail D Lewis, MS, van der Horst, Tina, MSc, Harle-Yge, Marie-Laurence, MSc, Althaus, Betsy L, PharmD, Kang, Yoon-Koo, Prof

“…Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is…”
Get full text

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial by Grothey, Axel, MD, Cutsem, Eric Van, Prof, Sobrero, Alberto, MD, Siena, Salvatore, MD, Falcone, Alfredo, MD, Ychou, Marc, MD, Humblet, Yves, MD, Bouché, Olivier, MD, Mineur, Laurent, MD, Barone, Carlo, MD, Adenis, Antoine, MD, Tabernero, Josep, MD, Yoshino, Takayuki, MD, Lenz, Heinz-Josef, MD, Goldberg, Richard M, MD, Sargent, Daniel J, PhD, Cihon, Frank, MS, Cupit, Lisa, MD, Wagner, Andrea, MD, Laurent, Dirk, DrMed

“…Summary Background No treatment options are available for patients with metastatic colorectal cancer that progresses after all approved standard therapies, but…”
Get full text

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial by Bennouna, Jaafar, MD, Sastre, Javier, MD, Arnold, Dirk, Prof, Österlund, Pia, MD, Greil, Richard, Prof, Van Cutsem, Eric, Prof, von Moos, Roger, MD, Viéitez, Jose Maria, MD, Bouché, Olivier, Prof, Borg, Christophe, MD, Steffens, Claus-Christoph, MD, Alonso-Orduña, Vicente, MD, Schlichting, Christoph, MD, Reyes-Rivera, Irmarie, MD, Bendahmane, Belguendouz, MD, André, Thierry, Prof, Kubicka, Stefan, Prof

“…Summary Background Bevacizumab plus fluoropyrimidine-based chemotherapy is standard treatment for first-line and bevacizumab-naive second-line metastatic…”
Get full text

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study by Pavel, Marianne E, Prof, Hainsworth, John D, Prof, Baudin, Eric, MD, Peeters, Marc, Prof, Hörsch, Dieter, Prof, Winkler, Robert E, MD, Klimovsky, Judith, MD, Lebwohl, David, MD, Jehl, Valentine, MSc, Wolin, Edward M, MD, Öberg, Kjell, Prof, Van Cutsem, Eric, Prof, Yao, James C, Dr

“…Summary Background Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown antitumour activity in patients with advanced…”
Get full text

Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954 by SCHUHMACHER, Christoph, GRETSCHEL, Stephan, OTT, Katja, HOELSCHER, Arnulf, SCHNEIDER, Paul M, BECHSTEIN, Wolf, WILKE, Hans, LUTZ, Manfred P, NORDLINGER, Bernard, VAN CUTSEM, Eric, SIEWERT, Jörg R, SCHLAG, Peter M, LORDICK, Florian, REICHARDT, Peter, HOHENBERGER, Werner, EISENBERGER, Claus F, HAAG, Cornelie, MAUER, Murielle E, HASAN, Baktiar, WELCH, John

“…Patients with locally advanced gastric cancer benefit from combined pre- and postoperative chemotherapy, although fewer than 50% could receive postoperative…”
Get full text

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer by Van Cutsem, Eric, Bang, Yung-Jue, Feng-yi, Feng, Xu, Jian M., Lee, Keun-Wook, Jiao, Shun-Chang, Chong, Jorge León, López-Sanchez, Roberto I., Price, Timothy, Gladkov, Oleg, Stoss, Oliver, Hill, Julie, Ng, Vivian, Lehle, Michaela, Thomas, Marlene, Kiermaier, Astrid, Rüschoff, Josef

“…Background In the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus chemotherapy improved median overall survival by 2.7 months in patients with…”
Get full text

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial by de Gramont, Aimery, Prof, Van Cutsem, Eric, Prof, Schmoll, Hans-Joachim, Prof, Tabernero, Josep, MD, Clarke, Stephen, Prof, Moore, Malcolm J, Prof, Cunningham, David, Prof, Cartwright, Thomas H, MD, Hecht, J Randolph, Prof, Rivera, Fernando, MD, Im, Seock-Ah, Prof, Bodoky, György, Prof, Salazar, Ramon, Prof, Maindrault-Goebel, Frédérique, MD, Shacham-Shmueli, Einat, MD, Bajetta, Emilio, Prof, Makrutzki, Martina, MD, Shang, Aijing, MD, André, Thierry, MD, Hoff, Paulo M, Prof

“…Summary Background Bevacizumab improves the efficacy of oxaliplatin-based chemotherapy in metastatic colorectal cancer. Our aim was to assess the use of…”
Get full text

A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas by Philip, Philip A, Buyse, Marc E, Alistar, Angela T, Rocha Lima, Caio MSPR, Luther, Sanjeev, Pardee, Timothy S, Van Cutsem, Eric

“…Devimistat (CPI-613 ) is a novel lipoate analog that inhibits the tricarboxcylic acid cycle at two key carbon entry points. Through its inhibition of pyruvate…”
Get full text

Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis by Burke, Carol A, Dekker, Evelien, Lynch, Patrick, Samadder, N. Jewel, Balaguer, Francesc, Hüneburg, Robert, Burn, John, Castells, Antoni, Gallinger, Steven, Lim, Ramona, Stoffel, Elena M, Gupta, Samir, Henderson, Alex, Kallenberg, Frank G, Kanth, Priyanka, Roos, Victorine H, Ginsberg, Gregory G, Sinicrope, Frank A, Strassburg, Christian P, Van Cutsem, Eric, Church, James, Lalloo, Fiona, Willingham, Field F, Wise, Paul E, Grady, William M, Ford, Molly, Weiss, Jennifer M, Gryfe, Robert, Rustgi, Anil K, Syngal, Sapna, Cohen, Alfred

“…In randomized trial involving 171 adults with familial adenomatous polyposis, the incidence of disease progression was not significantly lower with combination…”
Get full text

Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy by HENDLISZ, Alain, VAN DEN EYNDE, Marc, DELATTE, Philippe, DELAUNOIT, Thierry, PERSONENI, Nicola, PAESMANS, Marianne, VAN LAETHEM, Jean-Luc, FLAMEN, Patrick, PEETERS, Marc, MALEUX, Geert, LAMBERT, Bieke, VANNOOTE, Jaarke, DE KEUKELEIRE, Katrien, VERSLYPE, Chris, DEFREYNE, Luc, VAN CUTSEM, Eric

“…Liver dissemination is a major cause of mortality among patients with advanced colorectal cancer. Hepatic intra-arterial injection of the beta-emitting isotope…”
Get full text

Value of Diffusion-Weighted Magnetic Resonance Imaging for Prediction and Early Assessment of Response to Neoadjuvant Radiochemotherapy in Rectal Cancer: Preliminary Results by Lambrecht, Maarten, M.D, Vandecaveye, Vincent, M.D., Ph.D, De Keyzer, Frederik, M.Sc, Roels, Sarah, M.D., Ph.D, Penninckx, Freddy, M.D., Ph.D, Van Cutsem, Eric, M.D., Ph.D, Claus, Filip, M.D., Ph.D, Haustermans, Karin, M.D., Ph.D

“…Purpose To evaluate diffusion-weighted magnetic resonance imaging (DWI) for response prediction before and response assessment during and early after…”
Get full text

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer by Shah, Manish A., Kang, Yoon-Koo, Thuss-Patience, Peter C., Ohtsu, Atsushi, Ajani, Jaffer A., Van Cutsem, Eric, Hoersch, Silke, Harle-Yge, Marie-Laurence, de Haas, Sanne Lysbet

“…Background Prespecified exploratory biomarker analyses of the phase II/III GATSBY study (NCT01641939) assessed whether patient subgroups experienced a survival…”
Get full text

Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis by OBA, Koji, PAOLETTI, Xavier, OHASHI, Yasuo, PIGNON, Jean-Pierre, ROUGIER, Philippe, SASAKO, Mitsuru, SAKAMOTO, Junichi, SARGENT, Daniel, SHITARA, Kohei, VAN CUTSEM, Eric, BUYSE, Marc, BURZYKOWSKI, Tomasz, ALBERTS, Steven, BANG, Yung-Jue, BENEDETTI, Jacqueline, BLEIBERG, Harry, CATALANO, Paul, LORDICK, Florian, MICHIELS, Stefan, MORITA, Satoshi

“…In investigations of the effectiveness of surgery and adjuvant chemotherapy for gastric cancers, overall survival (OS) is considered the gold standard…”
Get full text

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial by Nordlinger, Bernard, Prof, Sorbye, Halfdan, MD, Glimelius, Bengt, Prof, Poston, Graeme J, MD, Schlag, Peter M, Prof, Rougier, Philippe, Prof, Bechstein, Wolf O, Prof, Primrose, John N, Prof, Walpole, Euan T, MD, Finch-Jones, Meg, MD, Jaeck, Daniel, MD, Mirza, Darius, MD, Parks, Rowan W, MD, Collette, Laurence, PhD, Praet, Michel, ScD, Bethe, Ullrich, MD, Van Cutsem, Eric, MD, Scheithauer, Werner, MD, Gruenberger, Thomas, Prof

“…Summary Background Surgical resection alone is regarded as the standard of care for patients with liver metastases from colorectal cancer, but relapse is…”
Get full text

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials by Lambrechts, Diether, Prof, Claes, Bart, MSc, Delmar, Paul, PhD, Reumers, Joke, PhD, Mazzone, Massimiliano, Prof, Yesilyurt, Betül T, MSc, Devlieger, Roland, Prof, Verslype, Chris, Prof, Tejpar, Sabine, Prof, Wildiers, Hans, Prof, de Haas, Sanne, PhD, Carmeliet, Peter, Prof, Scherer, Stefan J, MD, Van Cutsem, Eric, Prof

“…Summary Background No biomarkers that could guide patient selection for treatment with the anti-VEGF monoclonal antibody bevacizumab have been identified. We…”
Get full text

Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009 by Poon, Donald, Dr, Anderson, Benjamin O, Prof, Chen, Li-Tzong, MD, Tanaka, Koichi, Prof, Lau, Wan Yee, Prof, Van Cutsem, Eric, Prof, Singh, Harjit, MD, Chow, Wan Cheng, Prof, Ooi, London Lucien, Prof, Chow, Pierce, MD, Khin, Maung Win, Prof, Koo, Wen Hsin, MD

“…Summary Asia has a disproportionately large share of the world's hepatocellular carcinoma (HCC), mainly because of the endemic status of chronic hepatitis B…”
Get full text